Loading clinical trials...
Loading clinical trials...
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merck Sharp & Dohme LLC
NCT07665424 · Osteoporosis, Osteoporotic Vertebral Compression Fractures
NCT07027306 · Osteoporotic Fractures, Osteoporosis
NCT06558188 · Osteoporosis, Postmenopausal, Osteoporosis
NCT07154719 · Musculoskeletal Abnormalities, Obesity, and more
NCT06449742 · Vertebral Fracture, Osteoporosis
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions